• Ulcerative Colitis Clinical Trial

    Qu Biologics has initiated an ulcerative colitis clinical trial to study new investigational treatment QBECO SSI.

  • Crohn's disease clinical trial

    Initial Week 8 and preliminary Week 16 summary now available.

  • A New Treatment Approach For Cancer

    Qu Biologics’ SSIs are designed to restore normal immune function and activate the patient’s own immune cells to target the cancer.


"The future of medicine lies in treatments that restore our body's innate capacity to heal."

~ Dr. Hal Gunn, CEO of Qu Biologics

Qu Biologics is at the forefront of a paradigm shift in the way we treat cancer and other immune-related disease. Rather than blocking or stimulating a single receptor or pathway, the company’s Site Specific Immunomodulators (SSIs) aim to restore the body’s normal immune response.

About Qu Biologics

Qu Biologics has discovered how our body’s immune response to acute infection helps our body clear cancer and other chronic inflammatory diseases. To learn more, read How SSIs Work. SSIs, which are derived from components of inactivated bacteria, are designed to activate the body’s innate immune response and restore normal immune function in the targeted organ or tissue to reverse the chronic inflammation underlying many chronic diseases including cancer, inflammatory bowel disease and other immune-related conditions. By restoring and empowering your own immune system, SSIs are designed to treat disease differently.

We bring excitement and passion to our work every day with the goal of creating treatments that will positively impact the lives of people living with chronic disease. Qu Biologics’ founder and CEO, Dr. Hal Gunn, is a clinician who for 20 years has worked to understand the link between our immune system and chronic disease, including cancer. Qu Biologics’ Chief Medical Officer Dr. Simon Sutcliffe, former CEO of the BC Cancer Agency and a distinguished clinician, scientist and leader in cancer control internationally, leads Qu’s growing clinical trial program.

We have initiated three Health Canada-approved clinical trials in Crohn’s disease, ulcerative colitis and recurrent lung cancer.

We have completed enrollment of our Crohn’s disease clinical trial. Based on the Week 8 and preliminary Week 16 results, QBECO SSI appears safe and well-tolerated and demonstrates consistently positive trends throughout the treatment period of the trial, successfully establishing proof-of-concept in Crohn’s disease and supporting continued development of QBECO SSI in inflammatory bowel disease.

We have completed enrollment of our first group of participants into our ulcerative colitis clinical trial. To learn more about the ulcerative colitis clinical trial visit www.quibd.com. To sign up for updates about future clinical trials in ulcerative colitis, please email ulcerativecolitis@quibd.com.

Past events:

Past events:

About SSIs Discovery

Our History

Qu Biologics was launched in 2007 by Dr. Hal Gunn and Rob Freeman.



Join a team of innovators who share a passion to make a difference.


How SSIs Work

SSIs are designed to restore your normal immune response.


Efficacy and Safety Studies

More than 270 patients have been treated with SSI therapy in a compassionate use program.